Beyond the bench: translating CRISPR into cancer medicines

“Our journey has taught us that the most important advances in gene editing are not measured by editing efficiency or novel molecular tools, but by our ability to translate those innovations into therapies that address unmet patient needs."

Over the past decade, gene editing has transitioned from scientific promise to therapeutic reality, creating new opportunities to address previously untreatable diseases. At the Gene Editing Institute, our experience developing a CRISPR-based strategy for cancer has reinforced the importance of identifying targets that are biologically compelling and clinically meaningful. At the same time, our close partnership with clinicians has provided critical insights into where current therapies fall short and where patients remain underserved. Together, these perspectives have taught us that successful translation depends on aligning scientific innovation with the needs of patients and the realities of clinical care.

Please enter your email to access content Read now